ArticleJournal of diabetes research2026
Shenlian (SL) Decoction Treat Diabetic Nephropathy by Regulating M1 Polarization of Macrophages and Pyroptosis of Renal Tubular Epithelial Cells.
Article in Journal of diabetes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Shenlian (SL) Decoction Treat Diabetic Nephropathy by Regulating M1 Polarization of Macrophages and Pyroptosis of Renal Tubular Epithelial Cells.Journal of diabetes research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeThe objective of this study is to investigate the efficacy of the Shenlian (SL) decoction on regulating cellular pyroptosis and macrophage M1 polarization in the treatment of diabetic nephropathy (DN), and to elucidate its mechanism of action through the use of animal and cellular experiments.
methodsThe potential targets for SL decoction were predicted using the TCMSP and Swiss Target databases. The differential genes for DN were obtained using the GeneCards database, and potential mechanisms for the treatment of DN with SL decoction were explored through enrichment analysis. The efficacy of SL decoction in the treatment of DN and its regulation of macrophage polarization and pyroptosis were evaluated in vivo using db/db mice. The RAW264.7 cell line and the TCMK-1 cell line were cultured in vitro. The objective was to investigate the effect of SL decoction on the inhibition of M1 macrophage polarization and scorched death of renal tubular epithelial cells (TECs).
resultsThe results of the enrichment analysis indicated that the Toll-like signaling pathway was a principal pathway in the treatment of DN with SL decoction. The results of animal and cellular experiments demonstrated that SL decoction has the potential to enhance renal function in patients with DN, while simultaneously reducing the concentration of serum inflammatory factors. Additionally, it was observed that SL decoction could inhibit the infiltration of macrophages and the polarization of macrophages into the M1 phenotype. Furthermore, the activation of the TLR4 signaling pathway and the pyroptosis of renal tubular cells were also inhibited by SL decoction.
conclusionThis study employed network pharmacology and in vivo and in vitro experiments to confirm that SL decoction can improve renal function in patients with DN. The results demonstrated that the mechanism of action of SL decoction is related to regulating the M1 polarization of macrophages in the DN kidney and inhibiting the pyroptosis of renal TECs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.